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synergistically with polymyxin to inhibit Gram
negative bacteria
Lorraine A Draper1, Paul D Cotter2,3*, Colin Hill1,2* and R Paul Ross2,3Abstract
Background: The emergence of bacterial drug resistance encourages the re-evaluation of the potential of existing
antimicrobials. Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a
broad spectrum antimicrobial activity. Here, we focussed on expanding the potential of lacticin 3147, one of the
most studied lantibiotics and one which possesses potent activity against a wide range of Gram positive species
including many nosocomial pathogens. More specifically, our aim was to investigate if lacticin 3147 activity could
be enhanced when combined with a range of different clinical antibiotics.
Results: Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited synergistic activity with
lacticin 3147. Checkerboard assays were performed against a number of strains, including both Gram positive and
Gram negative species. The resultant fractional inhibitory concentration (FIC) index values established that, while
partial synergy was detected against Gram positive targets, synergy was obvious against Gram negative species,
including Cronobacter and E. coli.
Conclusions: Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target
specificity of the lantibiotic, while also reducing polymyxin use due to the lower concentrations required as a result
of synergy.
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The challenge presented by the emerging problem of
antibiotic resistance is a significant one. One approach
has been to identify new bactericidal agents while
another has involved a re-examination of the poten-
tial of previously identified antimicrobials. With this
latter route in mind, there has been a particular focus
on assessing and enhancing the benefits of applying
lantibiotics in clinical settings [1,2]. Lantibiotics are
ribosomally synthesised antimicrobial peptides that are
subjected to post-translational modification, resulting in
the presence of unusual amino acids including intramo-
lecular lanthionine and β-methyl lanthionine bridges.
These bridges are formed through a two-step process that
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reproduction in any medium, provided the orresidues to dehydroalanine (dha) and dehydrobutyrine
(dhb), respectively. The subsequent reaction of these
modified amino acids with intrapeptide cysteines results
in the formation of lanthionine (Ala-S-Ala; in the case of
dha) or β-methyl-lanthionine (Abu-S-Ala; in the case of
dhb) bridges (for reviews see [3-5]). Lacticin 3147 is a two
peptide lantibiotic which exhibits broad spectrum activity
against Gram positive targets. The two lacticin 3147 pep-
tides, Ltnα and Ltnβ, work synergistically in a 1:1 ratio
[5,6]. Ltnα first binds to the precursor of peptidoglycan
production, lipid II, with Ltnβ subsequently interacting
with this complex. The net effect is the inhibition of pep-
tidoglycan synthesis and the formation of a membrane
depolarising pore [7].
Some lantibiotics are active at single nanomolar
levels against particular targets and several lantibiotics
inhibit drug–resistant Gram positive pathogens, in-
cluding methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and activity can be enhanced through genetic alter-
ation and, thus, they are considered to be viable
alternatives to traditional antibiotics [1]. Lacticin 3147
inhibits many Gram positive pathogens including
Listeria monocytogenes, Staphylococcus aureus and
Clostridium difficile as well as a variety of streptococci,
enterococci and mycobacteria [8-10]. However, to date,
the inhibition of Gram negative species by lacticin
3147 has not been reported. This is most often attrib-
uted to the presence of the outer membrane, which
prevents access of the lantibiotic to the cytoplasmic
membrane.
There are many potential benefits associated with
identifying antibiotics that function synergistically with
lacticin 3147. While antibiotic resistance has become a
major obstacle, significant resistance to lacticin 3147
has yet to be reported and thus the use of antibiotic-
lacticin 3147 combinations may prevent/overcome
the emergence of resistance. Furthermore, certain
antibiotic-lacticin 3147 combinations may allow for a
broader range of species to be targeted. Here we assess
the impact of combining lacticin 3147 with a variety of
clinical antibiotics and establish that lacticin 3147 ex-
hibits synergistic activity in combination with either
polymyxin B or polymyxin E.Figure 1 Antibiotic disc-based assessment of lacticin 3147 and polym
polymyxin B and polymyxin E were placed on agar plates swabbed with E.
added to additional discs containing the respective polymyxins and to blan
duplicate experiments and are expressed as total area of inhibitory zone exResults
Sensitivity of bacteria to lacticin 3147 and antibiotics
in combination
To determine whether lacticin 3147 could work synergistic-
ally with a variety of clinically utilised antibiotics, we used
antibiotic disc assays to assess the potency of individual an-
tibiotics (cefotaxime, novobiocin, cefoperazone, teicoplanin,
ceftazidime, cefaclor, cephradine, cefaclor (30 μg), bacitra-
cin, imipenem, fusidic acid (10 μg), penicillin G (5 μg),
oxacillin (1 μg), colistin sulphate (polymyxin E) (25 μg) and
polymyxin B (300 U)), in the presence and absence of
lacticin 3147. It was evident that lacticin 3147 had the abil-
ity to enhance the activity of a number of the antibiotics
tested (data not shown) but the benefits of combining
lacticin 3147 with polymyxin B or polymyxin E were par-
ticularly obvious (Figure 1). In the case of the representative
Gram positive and negative strains, E. faecium DO and E.
coli EC101, the diameters of the zones of inhibition were
increased by over 180% and by over 121%, respectively.
Indeed, in the case of E. faecium DO, combining sub-
inhibitory concentrations of the individual antimicrobials
resulted in the formation of a zone of clearing (Figure 1).
Based on these preliminary experiments it was apparent
that the benefits of combining lacticin 3147 with either
polymyxin B or E merited further examination. We used
broth based microtitre plate assays to determine minimumyxin B/E sensitivity and synergy. Antibiotic discs infused with
faecium DO and E. coli EC101. Lacticin 3147 (1.2, 1.9 or 2.5 μg) was
k, non-polymyxin containing, controls. Results are the outcome of
pressed in mm2.
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against a range of Gram negative and representative Gram
positive strains (Table 1). It was apparent that a combin-
ation of lacticin 3147 and polymyxin B or E had an indiffer-
ent effect (FIC = 1.25 and 1.125 respectively) against
Salmonella Typhimurium UK1 and an antagonistic effect
(FIC > 4) was observed in the case of the LT2 strain. How-
ever, combining these antimicrobials against other targets
gave more positive results. Indeed, a high level of synergy
was observed against Cronobacter sakazakii strain 6440,
with an FIC index corresponding to 0.250 for a lacticin
3147 and polymyxin B combination and 0.062 for a lacticin
3147 and polymyxin E combination. FIC values here were
determined on the basis of the reduction in MIC values for
the polymyxins alone as an MIC value for lacticin 3147
could not be determined as it is not active against C.
sakazakii, even at the highest level tested (924μg/ml).
However, it can be established that the FIC is <0.312 for
lacticin 3147 in combination with polymyxin B and <0.125
when combined with polymyxin E.
Corresponding studies with three E. coli strains again
revealed synergism between lacticin 3147 and the
polymyxins. An FIC index value of 0.248 was obtained
when lacticin 3147 and polymyxin B were combined
against 0157:H- while the corresponding lacticin 3147
and polymyxin E FIC value was 0.188. When lacticin
3147 and polymyxin B were combined against E. coli
DH5α and EC101, FIC indices of 0.188 and 0.5 were
obtained, respectively. In addition, an FIC index of 0.188
was determined when lacticin 3147 and polymyxin E
were combined for these two target strains.
A number of additional assays were carried out in order
to determine if the benefits of combining lacticin 3147 and
the polymyxins in broth extended to Gram positive targets.
For this purpose Bacillus cereus 8079, Enterococcus faecium
DO and Staphylococcus aureus 5247 were selected asTable 1 MIC data for lacticin 3147, polymyxin B and polymyx
Organism
Lacticin
3147
Polymyxin
B
Polymyxin
E
Salmonella Typhimurium UK1 924 0.0586 0.0586
Salmonella Typhimurium LT2 231 0.3125 0.4688
Cronobacter sakazakii DPC 6440 >924 0.3125 0.3125
E. coli 0157:H- 231 0.0586 0.0781
E. coli DH5α 462 0.0781 0.0781
E. coli EC101 462 0.0781 0.0781
E. faecium DO 0.9625 >375 >375
B. cereus 8079 3.85 187.5 375
S .aureus 5247 15.4 187.5 >375
FIC figures have been calculated as a result of triplicate experiments and indicate as
between the combined antimicrobials. *FIC index which includes the reduction in la
the presence of polymyxin.representative indicator strains. It was established that,
while some partial synergy between lacticin 3147 and poly-
myxin B was observed with respect to B. cereus 8079 and S.
aureus 5247 (FIC = 0.62 and 0.75, respectively), the other
combinations resulted in an additive or indifferent outcome.
Given that the most notable outcome from the study
was the synergistic activity of lacticin 3147 and the
polymyxins against some Gram negative targets, further
investigations were carried out to determine how the re-
spective components of lacticin 3147, i.e. Ltnα and Ltnβ,
perform individually in the presence of polymyxin B/E.
Selecting the sensitive strain E. coli 0157:H- as a target,
we were able to evaluate the contribution of the individ-
ual α and β peptides to this phenomenon (Table 2).
Taking into consideration the molecular weights and 1:1
ratio at which α and β are combined, we can derive the
relative amount (μg/ml) of each individual peptide
present when lacticin 3147 (Ltnα and Ltnβ combined in
a 1:1 ratio) is synergistic with polymyxin B/E. With this
information we can compare the action of α and β alone
to the same amount of each peptide present in whole
lacticin 3147 in each case of synergy. Although various
degrees of synergy exist due to the different combina-
tions and concentrations assessed, only those that
yielded the greatest synergy with respect to lacticin 3147
are listed in Table 1. Obtaining such a high degree of
synergy was not possible with the single peptides, Ltnα
and Ltnβ. For this reason additional synergy values/FIC
data for lacticin 3147 in combination with polymyxin B
and E has been included in Table 2. This provides a
means by which the contribution of the individual
lacticin 3147 components can be derived by focusing on
a fixed level of polymyxin B/E in each case of synergy.
Hence, it is apparent that, when combined with a set
concentration of polymyxin B and E, 6 times more Ltnα
alone is required to achieve the level of synergy obtainedin E alone and in combination
MIC (μg/ml)
Lacticin 3147/ FIC Lacticin 3147/ FIC
Polymyxin B Polymyxin E
924/0.015 1.25d 924/0.0073 1.125d
No MIC >4e No MIC >4e
57.75/0.0781 0.250 (<0.312)*a 57.75/0.0195 0.062 (<0.125)*a
28.875/0.0073 0.250a 28.875/0.0049 0.188a
28.875/.0098 0.188a 28.875/0.0098 0.188a
14.4375/.0391 0.5a 28.875/0.0098 0.188a
0.9625/23.4375 1c 0.9652/23.4375 1c
1.925/23.4375 0.62b 3.85/375 2d
7.7/46.875 0.75b 15.4/23.4375 1c
ynergy, bfor partial synergy, cadditive effects, dindifference, and eantagonism
cticin 3147 MIC from the highest level tested to that which achieves an MIC in
Table 2 MIC data for lacticin 3147, and its individual peptides Ltnα and Ltnβ, polymyxin B and polymyxin E alone and
in combination
E.coli 0157:H-
MIC (μg/ml)
Lacticin 3147 Polymyxin B Polymyxin E Lacticin 3147/ FIC Lacticin 3147/ FIC
Polymyxin B Polymyxin E
231 (37.5 μM) 0.0586 0.0781 28.875/0.0073 0.250a 28.875/ 0.0049 0.188a
(α :124.74, Β: 106.26) 28.875 / 0.0147* 0.376*a 14.4375 / 0.0195* 0.312*a
Ltnα Polymyxin B Polymyxin E Ltnα/ FIC Ltnα/ FIC
Polymyxin B Polymyxin E
187.11 (56.25 μM) 0.0586 0.0781 93.555 / 0.0073 0.625b 46.7775/ 0.0195 0.500a
(1.5 X Ltnα) (6.0 X Ltnα in combin.) (6.0 X Ltnα in combin.)
Ltnβ Polymyxin B Polymyxin E Ltnβ/ FIC Ltnβ/ FIC
Polymyxin B Polymyxin E
495.88 (175 μM) 0.0586 0.0781 61.9850 / 0.0147 0.376a 30.9925 / 0.0195 0.313a
(4.7 X Ltnβ) (4.7 X Ltnβ in combin.) (4.7 X Ltnβ in combin.)
FIC figures have been calculated as a result of triplicate experiments and indicate asynergy and bpartial synergy effects.*Alternative MIC and FIC data that allow for
fixed levels of polymyxin across antimicrobial combinations, thus allowing for the calculation of the involvement of Ltnα and Ltnβ in synergy with polymyxin.
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4.7 times Ltnβ alone is required to achieve a corre-
sponding level of activity in the absence of Ltnα. Inter-
estingly the reverse is seen when you consider the
individual action of Ltnα and Ltnβ alone, in the absence
of polymyxin. In this situation only 1.5 times the amount
of Ltnα is required, while 4.7 times Ltnβ is needed to
achieve an MIC relative to their contribution when both
lacticin 3147 peptides are present.
Discussion
We undertook a series of investigations to determine
whether lacticin 3147 acts synergistically with a range of
clinically important antibiotics. Antibiotics encompassing
many families and modes of action were chosen, including
cephalosporins, polypeptides, glycopeptides, carbenems,
and quinolones. Following this initial screen, it became
clear that lacticin 3147 and the polymyxins acted
synergistically.
Polymyxins are a group of polypeptide antibiotics
that exclusively target Gram negative microorganisms.
The five distinct members of this group, polymyxin
A-E, were discovered in 1947 and are produced non-
ribosomally by different Bacillus polymyxa species [11].
Polymyxin B and polymyxin E (also referred to as colis-
tin), have been used in clinical practice for decades in
otic and ophthalmic solutions [12,13]. Polymyxins are
decapeptide antibiotics which consist of a heptapeptide
ring, with polymyxin E differing from polymyxin B only
by the presence of D-Leu in lieu of a D-Phe. This ring is
linked to a tripeptide side-chain which carries an
aliphatic chain attached via an amide bond to the
amino terminus [14]. The polymyxins carry five positivecharges due to the presence of L-α-γ-diaminobutyric
acids [11] and it has been established that the amphi-
philic nature of this molecule gives it the ability to
interact, bind and traverse the Gram negative outer
membrane. The target molecule is lipopolysaccharide
(LPS) [15], and specifically the lipid A component
[16,17]. The polymyxins dissociate protective divalent
cations from their association with anionic LPS. This
displacement permeabilises the Gram negative outer
membrane to allow the polymyxins, or other cationic
peptides, to form pores [18]. It should be noted, how-
ever, that the use of polymyxins in clinical settings has
been restricted to use only where drug resistant patho-
gens have been encountered. This is due to the toxicity,
primarily nephro- and neuro-toxicity, associated with its
use [19], although this toxicity has been suggested to be
dose dependent [20]. Nonetheless, the polymyxins are,
in many cases, the only antibiotics capable of overcoming
specific drug resistant pathogens such as Pseudomonas
aeruginosa and Acinetobacter baumannii in cystic fibrosis
patients (for reviews see [21-23]). For this reason the poly-
myxins cannot be ignored, but strategies that could reduce
the dose needed for these antibiotics to be effective are
highly desirable.
A number of studies have investigated the conse-
quences of combining various antibiotics with poly-
myxins. Antimicrobial agents such as miconazole [24],
rifampicin [25,26] meropenem, ampicillin-sulbactam,
ciprofloxacin, piperacillin-clavulanic acid, imipenem,
amikacin, and gentamicin [27] ciprofloxacin [28] tri-
methoprim, trimethoprim-sulfamethoxazole, and vanco-
mycin [29], to name but a few, have been the focus of
studies to assess if they can work synergistically with
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pounds synergistic with polymyxin E [30]). To date the
only lantibiotic to have been investigated in this way is
nisin, which displays synergy with polymyxin B and poly-
myxin E against Listeria and E. coli [31,32]. Nisin has also
been shown to function synergistically when combined
with polymyxin E (and clarithromycin) against Pseudo-
monas aeruginosa [33]. Combination studies have also re-
cently revealed that lacticin 3147 and the lactoperoxidase
system (LPOS) successfully inhibited growth of Cronobacter
spp. in rehydrated infant formula [34]. Lacticin 3147, like
nisin, is a food grade bactericidal agent obtained from the
GRAS organism Lactococcus lactis. Notably, however, it dif-
fers from nisin with respect to its target specificity and its
greater potency against a number of species [10]. Also the
mechanism of action contrasts from the single nisin pep-
tide, in that it requires the interaction of two peptides, Ltnα
and Ltnβ, for optimal bactericidal activity.
Here, we report the first study to investigate whether
synergy can occur between polymyxin(s) and a two-
component lantibiotic. Not only do we reveal that syn-
ergy is apparent against a range of strains tested, we also
investigated the individual contributions of Ltnα and
Ltnβ. We established that, when combined with poly-
myxin B/E, the levels of lacticin 3147 required to inhibit
Gram negative species are equivalent or lower than the
levels of lacticin 3147 alone against many Gram positive
targets. Thus, in the presence of 0.3125 μg/ml polymyxin
B/E, the concentration of lacticin 3147 required to
inhibit Cronobacter spp. is less than the lacticin 3147
MIC for Mycobacterium avium subsp. paratuberculosis
(MAP) ATCC 19698 or Mycobacterium kansasii CIT11/
06 [8]. Similarly the MIC of lacticin 3147 (alone) against
many S. aureus (which includes many of the nosocomial
pathogens: methicillin-resistant S. aureus (MRSA), S. aur-
eus with intermediate resistance to vancomycin (VISA), S.
aureus with heterogenous vancomycin intermediate resist-
ance (hVISA)) [10,35], is greater than that required to in-
hibit E. coli species when in the presence of a polymyxin. It
is also important to note that synergy with lacticin 3147
may provide a means of reducing the dose of polymyxins
required to inhibit specific targets, thereby addressing
polymyxin-associated toxicity issues. For example, 8-fold
and 16-fold lower levels of the polymyxins are required to
inhibit E. coli and Cronobacter when in the presence of
lacticin 3147. Furthermore a recent study by Naghmouchi
et al., has shown that in addition to its role in providing
synergy with polymyxin E, the lantibiotic nisin appears,
at certain concentrations, to eliminate its toxicity, as
seen in Vero cell lines [36]. Having established the role
lacticin 3147 has in polymyxin synergy, further investi-
gations are warranted in order to ascertain if such
toxicity preventing attributes are common amongst
lantibiotics.As with previous studies [37], the solo activities of
polymyxin B and polymyxin E against the strains tested
here are very similar. With respect to the dual action of
lacticin 3147 and polymyxins, it appears that the lacticin
3147-polymyxin B combination has the greater potency
against Gram positive targets but that the lacticin 3147-
polymyxin E combination has a greater effect against
Gram negative strains. Thus, the single amino acid dif-
ference between the two polymyxin peptides appears to
have an impact on its bactericidal action and target spe-
cificity when combined with lacticin 3147. It was also
notable that the lacticin 3147 sensitivity of Gram posi-
tive microorganisms such as Enterococcus faecium DO,
which is already highly sensitive to lacticin 3147, is not
enhanced by the presence of the polymyxins. However,
in the case of the strains that are relatively more lacticin
3147 resistant, the benefits of adding polymyxin B (espe-
cially with respect to Gram positive strains) and poly-
myxin E (especially for Gram negative strains) is most
apparent. It is interesting to note that this phenomenon
does not correlate with results obtained during the initial
agar based disc assay screen, where the opposite pattern
was observed. However, it is acknowledged that the
agar-based screen is a much cruder assay, and in that in-
stance polymyxin concentrations were fixed and only
lacticin 3147 concentrations were altered. Moreover, no
FIC data can be derived and so increased zone sizes may
not represent the optimal combination of the antimicro-
bials as obtained through checkerboard assays. The
mechanism by which this synergy occurs with respect to
Gram negative targets is presumably based on the action
of polymyxin permeabilising the outer membrane to
allow lacticin 3147 to gain access to the cytoplasmic
membrane and its lipid II target [38]. However, a
phenomenon concerning the synergy between polymyxin
B/E and the singular peptides Ltnα and Ltnβ is also un-
veiled during this study. Considering the action of the
singular peptides in the absence of polymyxin, a greater
quantity of Ltnβ alone, than Ltnα alone, is required to
inhibit E. coli (4.7 times versus 1.5 times respectively).
This is logical in that Ltnα has been shown to have
greater solo activity, and can bind to lipid II and prevent
peptidoglycan synthesis [7]. However in the presence of
polymyxin B/E, Ltnα needs to be added at a 6 times
greater concentration to bring about an inhibitory effect
equal to that achieved by Ltnα:Ltnβ combined. In con-
trast, Ltnβ only needs to be added at a 4.7 fold greater con-
centration to compensate for the absence of Ltnα and thus
Ltnβ seems more potent than Ltnα in the presence of ei-
ther polymyxin. It is not clear if this is due to the potency
of Ltnα being slightly compromised by the activity of the
polymyxins or is a reflection of a particularly beneficial
interaction between these antibiotics and Ltnβ. Additional
studies will be required in order to investigate this further.
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Regardless of the mechanism involved, this study docu-
ments a means by which lacticin 3147 can be combined
with polymyxins in order to effectively inhibit some Gram
negative species. There are a number of practical implica-
tions to these findings but these will require in vivo analysis.
One outcome may be to ultimately facilitate the use of
lower concentrations of polymyxins in situations where the
levels currently employed are of concern from a toxicity
perspective. Alternatively, enhancing the spectrum of
lacticin 3147 to include Gram negative targets could have
benefits with respect to, for example, the treatment of
bovine mastitis. While lacticin 3147 has been established as
being effective with respect to controlling bovine mastitis
caused by Gram positive microorganisms, reducing levels
of S. aureus, Streptococcus dysgalactiae or Streptococcus
uberis [39,40],mastitis can also be caused by Gram negative
species and in particular by E. coli species [41,42], against
which lacticin 3147 has limited efficacy. E. coli can be
considered the quintessential environmental pathogen with
respect to mastitis. Infections tend to result in acute and
often severe clinical mastitis and account for as many as
30% to 40% of clinical mastitis cases [43]. Combining
lacticin 3147 with low levels of a polymyxin could provide a
means of broadening target specificity, for example in the
treatment of mastitis, while keeping the concentrations of
antimicrobial employed to a minimum.
Methods
Cultures and growth conditions
Salmonella Typhimurium UK1, Salmonella Typhimurium
LT2, Escherichia coli 0157:H- , E. coli EC101, E. coli DH5α
(University College Cork (UCC) culture collection) and
Cronobacter sakazakii 6440 (Dairy Products Research
Centre (DPC) collection) were grown in Luria-Bertani (LB)
broth and agar at 37°C, while Bacillus cereus 8079 (DPC
collection) and Enterococcus faecium strains DO [44],
EC538, EC295 and EC725 (British Society for Antimicrobial
Chemotherapy (BSAC)) were grown in Brain Heart
Infusion (BHI) broth and agar (Oxoid Ltd., Basingstoke,
Hampshire, England) at 37°C. Staphylococcus aureus strains
ST528, ST523, ST530, ST291, ST534 (BSAC) and 5247
(DPC collection) were also grown at 37°C but with aeration
in cation supplemented Mueller Hinton broth and
Mueller Hinton agar (Oxoid Ltd., Basingstoke, Hampshire,
England). Lactococcus lactis MG1363 (UCC collection) was
grown at 30°C without aeration in M17 broth (Oxoid Ltd.,
Basingstoke, Hampshire, England) supplemented with 0.5%
(wt/vol) glucose (GM17).
Antimicrobials
Cefoperazone, Cefaclor, Teicoplanin, Bacitricin, Colistin
sulphate (polymyxin E), polymyxin B, oxacillin and fusidic
acid antimicrobial susceptibility discs were purchased fromOxoid. Polymyxin B and colistin sulphate (polymyxin E)
were obtained from Sigma-Aldrich while lacticin 3147 was
purified using the following procedure: TYG media
(tryptone, 2.5 g/l; yeast extract, 5.0 g/l; glucose, 10 g/l;
β-glycerophosphate, 19.0 g/l; MgSO4 x 7H2O, 0.25 g/l;
MnSO4.4H2O, 0.05 g/l) was passed through 500 g XAD-16
beads (Sigma-Aldrich Company Ltd., Dorset, England) in
order to remove all hydrophobic components. An overnight
culture of L. lactis MG1363.pMRC01.pOM02 [45] was then
used to inoculate 1L of the modified TYG broth (1% inocu-
lum) and incubated at 30°C overnight. The cells were sub-
sequently harvested by centrifugation (7000 g for 20 min)
and resuspended in 250ml 70% propan-2-ol, pH2 (adjusted
to pH2 with addition of conc. HCl). Following stirring at
4°C for four hours the cell debris was removed by centrifu-
gation and the supernatant was subjected to rotary evapor-
ation (50 mbar at 40°C) to reduce the volume to ~60ml
via removal of propan-2-ol. The resultant preparation
was applied to a 10 g/60ml Strata C-18E Giga-Tube
(Phenomenex, Cheshire, UK) after pre-equilibration with
60ml methanol followed by 60ml water. The column was
subsequently washed with 120ml of 30% ethanol and the
lantibiotic was then eluted from the column via addition of
100ml of 70% propan-2-ol, pH2. From the 100ml prepar-
ation, 20ml volumes were subjected to rotary evaporation
in order to reduce them to ~1.7ml through removal of
propan-2-ol. Aliquots of 1800 μl were then applied to a
Phenomenex (Phenomenex, Cheshire, UK) C12 reverse
phase (RP)-HPLC column (Jupiter 4 μ 90Å 250 × 10.0 mm,
4 μm) previously equilibrated with 25% propan-2-ol
containing 0.1% trifluoroacetic acid (TFA). The column
was then developed in a gradient of 30% propan-2-ol
containing 0.1% TFA to 60% propan-2-ol containing 0.1%
TFA in 4 to 40 min at a flow rate of 1.2ml/min. Fractions
containing Ltnα and Ltnβ were collected after each HPLC
run and stored under nitrogen gas. The Ltnα and Ltnβ
containing fractions were pooled separately and subse-
quently subjected to rotary evaporation to remove all
propan-2-ol before freeze-drying of the peptides. The Ltnα
and Ltnβ peptides were weighed in μg quantities using a
Mettler UMT2 micro-balance.
Antibiotic disc-based assessment of antimicrobial
sensitivity and synergy
The sensitivities of S. Typhimurium LT2, C. sakazakii 6440,
S. aureus, and E. faecium strains to a variety of antibiotics
were determined by antibiotic disc diffusion assays as
described previously [46]. Briefly, stationary-phase cultures
(16 h) were diluted to 107 CFU/ml and swabbed onto
Mueller Hinton, LB or BHI agar plates. Six mm antibiotic
discs (Oxoid) infused with specific antibiotics were placed
on the agar plates. On the same plate lacticin 3147 (1.2, 1.9
or 2.5 μg) was added to a second antibiotic-containing
disc and to a blank disc (control). Following overnight
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inhibition were measured. The antibiotic discs employed
included cefotaxime, novobiocin, cefoperazone, teicoplanin,
ceftazidime, cefaclor, cephradine, cefaclor (30 μg), bacitra-
cin, imipenem, fusidic acid (10 μg), penicillin G (5 μg),
oxacillin (1 μg), colistin sulphate (polymyxin E) (25 μg) and
polymyxin B (300U).
Minimum inhibitory concentrations
MIC determinations were carried out in triplicate in 96
well microtitre plates as previously described by
Wiedemann et al., 2006. Briefly, bacterial strains were
grown overnight in the appropriate conditions and
medium, subcultured into fresh broth and allowed to
grow to an OD600nm of ~0.5. Serial two-fold dilutions of
the lacticin 3147, polymyxin B or colistin sulphate were
made in the growth medium of the respective strain.
Bacteria were then diluted and added to each microtitre
well resulting in a final concentration of 105 cfu/ml in
each 0.2 ml MIC test well. After incubation for 16 h at
37°C, the MIC was read as the lowest peptide concentra-
tion causing inhibition of visible growth.
Checkerboard assay for combining antimicrobials
In order to analyse combinations of two different anti-
microbials (e.g. X and Y), the minimum inhibitory con-
centration of each antimicrobial has to be defined
against a specific strain. Once this is known a 2-fold ser-
ial dilution of X is made horizontally in broth (50 ul) in
a microtitre plate beginning at 8 x MIC for X. In a sec-
ond microtitre plate, a similar dilution of Y is created
and then 50 ul of this is added vertically to the original
microtitre plate containing the dilution of X. Bacteria
were then added in the same fashion as performed for
the singular peptide minimum inhibitory assays de-
scribed previously. Fractional Inhibitory Concentration
(FIC) index is defined by the following equation: FIC =
FICX + FICY = (X/MICX) + (Y/MICY). Where (X) is the
lowest level of antimicrobial X in combination with an-
other to achieve an inhibitory effect, while (MICx) is the
MIC of that antimicrobial alone for the bacterial strain
under investigation. FIC index results are interpreted as
follows: FIC ≤ 0.5 is synergy, 0.5 < FIC ≤ 0.75 is partial
synergy, 0.75 < FIC ≤ 1.0 is additive, FIC >1.0 is indiffer-
ent and FIC > 4 is antagonistic [47].
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